Clinical trials: Adnexal Tumor
Breast Neoplasms, Uterine Cervical Neoplasms
Early Detection of Cancers in Low Resource Countries
The purpose of this study is to implement a community-based combined program for early detection of breast, cervical, ovarian and endometrial cancer in low-resource countries delivered through a free standing or a mobile Well…
- Conditions
- Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms
- Trial name
- NCT01178736
- Testing
- Breast Cancer Screening and Diagnosis, Cervical Cancer Screening and Diagnosis, Ovarian Cancer Screening and Diagnosis
- Where
- 3 sites in Brazil, Cambodia and 1 more
- Volunteers
- 36,000 people, healthy volunteers welcome
- Sponsor
- Woman's Cancer Foundation
Ovarian Cancer
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
This study is an open-label, multicenter, umbrella study aimed to evaluate the combined, biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and Nab-paclitaxel in patients with…
- Trial name
- BRIGHT (NCT05044871)
- Testing
- Pamiparib, Bevacizumab, Tislelizumab
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Tongji Hospital
Fallopian Tube Cancer, Ovarian Cancer
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have refractory…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00053833
- Testing
- irinotecan
- Where
- 100 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Polycystic Ovary Syndrome, Assisted Reproduction
Mitochondrial DNA in Fresh Versus Frozen Embryo Culture Media of PCOS Women Undergoing In Vitro Fertilization
Ninety women with PCOS candidate for ICSI were randomized to 2 groups:Group A: fresh samples of PCOS patients undergoing IVF (no= 45) and Group B: frozen samples of PCOS patients undergoing IVF (no= 45).
- Trial name
- NCT03820167
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Ovarian Cancer, Breast Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01623349
- Testing
- BKM120 and Olaparib, BYL719 and Olaparib
- Where
- 5 sites in United States
- Volunteers
- 118 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Peritoneal Cancer
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
To determine treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies: Gynecologic cancers (ovarian, primary peritoneal or fallopian…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Uterine Cancer
- Trial name
- HIPEC/IPHC (NCT02349958)
- Testing
- HIPEC: MMC 30mg @ T0, 10mg @ T45min, HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0, HIPEC: CDDP 75 mg/m2 @T0
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bay Area Gynecology Oncology
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors
RATIONALE: Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer
- Trial name
- NCT00274950
- Testing
- bleomycin sulfate, carboplatin, cisplatin
- Where
- 20 sites in Ireland, United Kingdom
- Volunteers
- 105 people
- Sponsor
- Children's Cancer and Leukaemia Group
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
There are more and more PARPi(PARP inhibitors) resistance for ovarian cancer patients after previous use of PARP inhibitors. Basic studies have found that there is synergistic effect of bevacizumab combined with PARPi.
- Trial name
- NCT05551208
- Testing
- fluzopanib and bevacizumab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chongqing University Cancer Hospital
Ovarian Cancer, Breast Cancer
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Background: All cells go through cycles which allow them to divide. In normal cells, checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (CHEK 2 (Chk1/2) stop cell division at various points to allow any damage to…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02203513
- Testing
- LY2606368
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Vulvar Cancer, Ovarian Cancer
Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery
The purpose of this study is to help test an idea designed to foster more supportive talk between providers (doctors or nurse practitioners), patients, and caregivers during an outpatient oncology appointment.
- Conditions
- Vulvar Cancer, Ovarian Cancer, Uterine Cancer, Vaginal Cancer
- Trial name
- PRECursOr (NCT05995860)
- Testing
- Intervention group triads
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Indiana University
Ovarian Cancer, Fallopian Tube Cancer
The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer
Cytomegalovirus (CMV), a widely prevalent virus in the general US population, has been shown to be associated with increased inflammation and mortality.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT03921658
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- University of Minnesota
Ovarian Cancer
Ovarian Cancer Individualized Scoring System Scoring System
This project aims at creating an individualized prognostic model using patient characteristics and disease features to determine disease prognosis using machine learning technology.
- Trial name
- OCISS (NCT05496517)
- Where
- 2 sites in Egypt
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Assiut University
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Polycystic Ovary Syndrome (PCOS), Insulin Resistance Syndrome
Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study
Purpose of the Study: This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS).
- Trial name
- PCOSMG53 (NCT07094776)
- Testing
- No intervention (observational study)
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Havva Betül Bacak
Ovarian Neoplasm, Fallopian Tube Neoplasms
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05257408
- Testing
- Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 381 people
- Sponsor
- Corcept Therapeutics
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
The main purpose of this study is to: Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus The study will also…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
- Trial name
- NCT03564340
- Testing
- Ubamatamab, Cemiplimab, Sarilumab
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 890 people
- Sponsor
- Regeneron Pharmaceuticals